Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global CAR-T B-Cell NHL Market Forecasts Report 2017 Featuring Axi-Cel, Juno, Kite Pharma & Novartis - Research and Markets

Research and Markets
Posted on: 08 Sep 17

The "CAR-T B-Cell NHL Global Market Forecast" drug pipelines has been added to Research and Markets' offering.

This report consists of a detailed Executive presentation (~177 slides) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies (per competitor) in adult r/r NHL B-cell type lymphomas (new cases) across 9 major Western markets to 2030. A patient-based flow methodology has been devised where two possible intervention scenarios for CAR-T introduction are visualised so that the optimum product positioning can be assessed. In addition, an up-to-date review of NHL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T NHL competitive landscape. Pricing, cost effectiveness, manufacturing and logistical considerations are also discussed. All assumptions are clearly provided.

Non-Hodgkin Lymphomas (NHLs) are a heterogeneous group of malignancies which have a wide range of histological appearances and clinical features. They are divided into two prognostic groups: Indolent lymphomas and Aggressive lymphomas. Of the B-cell type aggressive forms, Diffuse large B-cell lymphoma (DLBCL) and Follicular lymphoma (FL) are common types accounting for around 65% of cases (WHO figures). DLBCL is most common in people over 50 and has a current 5-year survival rate around 62%. It is estimated that approximately 26,000 people will be diagnosed with DLBCL in the United States in 2016.

There are many treatment strategies for NHLs including radiation therapy, chemotherapy (e.g. CHOP, CVP) and various combinations with rituximab or other anti-CD20 mAbs. Stem cell or bone marrow transplant is an also option for certain patients. There is a high unmet need within the relapsing/refractory subset of patients who have an extremely poor prognosis.

New treatments for NHL under investigation include the checkpoint inhibitors (PD-1 and PD-L1), therapeutic vaccines (CDX-301, SD101) and CAR-T cell therapies: Axi-Cel/KTE-C19, JCAR017 and CTL019 (tisagenlecluecel-T) developed by Kite Pharma, Juno Therapeutics and Novartis Pharmaceuticals respectively. Kite's KTE-C19 has already been filed in the US for DLBCL with Novartis and Juno expected to follow closely in both US and the EU.

Companies Mentioned

  • Axi-Cel
  • Juno
  • Kite Pharma
  • Novartis

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/88p23l/cart_bcell_nhl

View source version on businesswire.com: http://www.businesswire.com/news/home/20170908005383/en/

Business Wire
www.businesswire.com

Last updated on: 08/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.